Jan 27, 2020
Bausch + Lomb and TerraCycle Partner to Launch Canada's First and Only Contact Lens Recycling Program
Oct 23, 2019
Bausch Health Licenses Clearside Biomedical's XIPERE(TM) (Triamcinolone Acetonide Suprachoroidal Injectable Suspension), An Investigational Treatment For Macular Edema Associated With Uveitis
Feb 25, 2019
Bausch + Lomb Announces FDA Approval Of LOTEMAX® SM (loteprednol Etabonate Ophthalmic Gel) 0.38% For The Treatment Of Postoperative Inflammation And Pain Following Ocular Surgery
Feb 19, 2019
Bausch Health Acquires Eton Pharmaceuticals' EM-100 Investigational Eye Drop For The Treatment Of Itchy Eyes Associated With Allergies
Nov 13, 2018
Bausch Health Will Expand Contact Lens Manufacturing Facilities In Rochester, NY And Waterford, Ireland
Jul 09, 2018
Bausch + Lomb Announces U.S. FDA Filing Acceptance For Loteprednol Etabonate Ophthalmic Gel, 0.38%
May 02, 2018
Bausch + Lomb ULTRA® Contact Lenses Receive FDA Approval for Extended Wear Indication
Apr 19, 2018
Bausch + Lomb Reports More Than Two Million Used Contact Lens Materials Recycled Through ONE by ONE Program
Jan 04, 2018
Sight Sciences Expands Surgical Portfolio with FDA Clearance of the OMNI(TM) Surgical System
Dec 22, 2017
Bausch + Lomb Receives FDA Approval of LUMIFY(TM) - The Only Over-The-Counter Eye Drop With Low-Dose Brimonidine For The Treatment Of Eye Redness
Dec 19, 2017
CRG, Gramercy Property Trust Complete Greenville Bausch + Lomb
Dec 18, 2017
Bausch + Lomb Begins Distribution Of VYZULTA(TM) (latanoprostene bunod ophthalmic solution), 0.024% To U.S. Wholesalers
Nov 02, 2017
Bausch + Lomb And Nicox Announce FDA Approval Of VYZULTA(TM) (latanoprostene Bunod Ophthalmic Solution), 0.024%
Aug 16, 2017
Valeant Receives FDA Confirmation Of Voluntary Action Indicated (VAI) Inspection Classification For Tampa Facility